Drugs / Faropenem Medoxomil
Faropenem Medoxomil
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00276042 | Jan 2006 → Jan 2007 | otitis media | Replidyne | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00255983 | Dec 2005 → May 2008 | chronic bronchitis | Replidyne | Terminated | No outcome recorded Stop: Business |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Faropenem Medoxomil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00276042 ↗ |
| Known as | A-0026 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1257070 ↗ |
| Known as | BAY-56-6854 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1257070 ↗ |
| Known as | Faropenem daloxate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1257070 ↗ |
| Known as | Fropenem daloxate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1257070 ↗ |
| Known as | SUN-A0026 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1257070 ↗ |
| Modality | Small molecule | — CHEMBL1257070 ↗ |
| Route | Oral | “Faropenem Medoxomil 600 mg PO, BID for 5 Days” NCT00255983 ↗ |